What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Ribociclib plus fulvestrant shows moderate benefit over current care, with significant improvements in progression-free survival (PFS) from 9.1 months to 14.6 months (HR 0.57) and overall survival (OS) from 32.5 months to 40.2 months (HR 0.73). However, the OS results are not statistically significant, indicating a modest margin of benefit.
Does the economic case hold at the expected price? — Cost effectiveness
The committee concluded that ribociclib plus fulvestrant is a cost-effective alternative to exemestane plus everolimus, with ICERs falling within the range typically considered cost-effective by NICE. The economic model used was appropriate, although uncertainties remain.
Is there quality-of-life evidence payers weigh? — Quality of life
While specific HRQoL data is not detailed, the committee notes that treatments extending survival while improving quality of life are important to patients. The evidence suggests that ribociclib plus fulvestrant is well-tolerated and preferred over alternatives like exemestane plus everolimus, which are associated with more severe side effects.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Ribociclib has a very good safety profile, with mostly mild or moderate adverse events reported. The committee noted that it is generally less toxic than exemestane plus everolimus, which is associated with more severe side effects like mouth ulcers.
Was the drug compared against what payers expect? — Comparator Selection
The primary trial (MONALEESA-3) compared ribociclib plus fulvestrant against placebo plus fulvestrant, which is acceptable but not ideal. The most relevant comparator, exemestane plus everolimus, was not directly tested, leading to reliance on indirect comparisons.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is relevant to Healthcare clinical practice, particularly the subgroup of patients who had prior endocrine therapy. However, the committee noted that the trial was not designed to detect treatment effects within subgroups, which introduces some limitations.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Ribociclib can be integrated into existing treatment pathways with minor adjustments. The committee noted that it fits well within the current treatment landscape for advanced breast cancer, requiring no significant new infrastructure.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model indicates that ribociclib plus fulvestrant has a manageable budget impact, aligning with Healthcare planning. The committee noted that the treatment is likely to be resource-efficient compared to alternatives.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on a well-conducted Phase 3 trial (MONALEESA-3) and supported by network meta-analyses. However, there are some methodological concerns regarding the indirect comparisons and the statistical power of subgroup analyses.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding the economic modelling and survival extrapolations, the committee noted that these uncertainties are manageable and do not undermine the overall positive assessment of ribociclib plus fulvestrant.
